arrow
A

Akio Suzuki

hokkaido university
H指数:34
被引数:4,822

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Proteinuria with extended VEGF inhibitor therapy in RAS-mutant metastatic colorectal cancer: incidence, interruptions, and exploratory survival analysis

RAS突变型转移性结直肠癌中VEGF抑制剂延长治疗期间的蛋白尿:发生率、中断情况及探索性生存分析

2026-08-040
OAAI
Prevalence, antimicrobial susceptibility, and virulence profiles of fluoroquinoloneresistant Escherichia coli isolated from companion animals in Sapporo, Japan

从日本札幌的伴侣动物中分离出的氟喹诺酮类耐药大肠杆菌的患病率,抗菌药敏性和毒力谱

2025-11-010
PRE
Effectiveness of polypharmacy measures consisting of a pharmacist check followed by a multidisciplinary team review in patients with poly-pharmacy admitted to a neurology ward

多重用药措施的有效性,该措施包括药师检查后进行多学科团队评审,适用于入住神经内科病房的多重用药患者。

2025-10-010
PRE
Response to the letter to the editor regarding “Changes in syndecan-1 concentration in the coronary sinus immediately after cardiac reperfusion reflect postoperative myocardial injury”

对编辑来信的回复,关于“心脏再灌注后冠状静脉窦中syndecan-1浓度的变化反映术后心肌损伤”

2025-08-280
PRE
Pyruvate–GPR31 axis induces LysoDC dendrite protrusion to M-cell pockets for effective immune responses

丙酮酸-GPR31轴诱导溶酶体DC树突突向M细胞囊袋以实现有效免疫应答

2025-07-310
OA
Cancer cachexia onset and survival outcomes in metastatic colorectal cancer: Comparative assessment of the asian working group for cachexia and the European palliative care research collaborative criteria, and utility of modified glasgow prognostic score

癌症恶病质发生及生存结局在转移性结直肠癌中的比较评估:亚洲恶病质工作组与欧洲姑息治疗研究合作组织标准的比较评估,以及改良格拉斯哥预后评分的应用价值

2025-07-250
OAAI
Changes in syndecan-1 concentration in the coronary sinus immediately after cardiac reperfusion reflect postoperative myocardial injury

心脏再灌注后冠状静脉窦中syndecan-1浓度的变化反映了术后心肌损伤

2025-06-290
PRE
Efficacy of triplet antiemetic prophylaxis against chemotherapy-induced nausea and vomiting in patients with soft tissue sarcomas receiving consecutive-day doxorubicin and ifosfamide therapy

软组织肉瘤患者在接受连续日多柔比星和异环磷酰胺疗法时,三联抗呕吐预防方案对化疗引起的恶心和呕吐的疗效

2025-03-130
PRE
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study

S-268019-b重组疫苗在1/2期基础-加强免疫研究中免疫应答的纵向分析

2025-03-050
OA